I
Antiviral
Its most-studied use, tested extensively against hepatitis B and C and other viral loads by improving the body's own immune response.
DC
Dendritic cells
The scouts that present threats and set the response.
Specimen № 02 · Thymosin Alpha-1 · Tα1 · Thymalfasin
The Thymus Peptide
That Drills Your Defenses
A field guide to Thymosin Alpha-1: a 28-amino-acid messenger from the thymus that trains the immune system to find viruses, cancer, and its own overreactions.
Thymosin Alpha-1 is a 28-amino-acid peptide the thymus gland makes on its own. Its synthetic form, Thymalfasin, is approved in more than 35 countries for hepatitis B and C and as a broad immune enhancer. In the United States it sits unapproved, yet it held FDA orphan-drug status from 1991 to 2006, and today it is one of the most-studied immune peptides in medicine.
Mechanism
A conductor, not a soldier
Tα1 does not attack anything itself. It tunes the immune orchestra, acting as a toll-like receptor agonist across myeloid and dendritic cells and steering the cell types that carry out both innate and adaptive defense.
T
T cells
Enhanced function and sharper adaptive targeting.
NK
Natural killer cells
Amplified innate defense against virus and tumor.
Three Properties
What decades of study keep showing
II
Autoimmune-mitigating
It calms an immune system that overreacts, rather than simply switching it on, which is why it reads as a regulator rather than a stimulant.
III
Anti-cancer
By amplifying natural killer cells and innate defenses, it supports the immune approach oncologists increasingly favor: strengthen the host, not just poison the tumor.
Orphan-Drug Trials · 1991–2006
Where the FDA allowed compassionate use
During its orphan-drug window, Tα1 was cleared for compassionate use across four clinical trials, in conditions where the immune system needed rebuilding:
Hepatitis B
Thymus gland absence in children
DiGeorge Syndrome
Hepatocellular carcinoma
Malignant melanoma
Dosing Protocol
As Dr. Schuster describes it
Two regimens he cites from Dr. Edwin Lee, who uses Tα1 routinely with patients. Both are given subcutaneously; intravenous administration is also possible.
Regimen A · Bi-weekly
1.6–3.2 mg
Subcutaneous, twice weekly.
Regimen B · Daily
400–600 mcg
Subcutaneous, once daily.
Loading & maintenance: consecutive daily dosing for the first one to two weeks, then a maintenance schedule of roughly every other week.
“Serious adverse reactions and known toxicity is basically none. Over 500,000 Americans have used it, with no severe side effects listed.”— Dr. Jason Schuster, citing a 2024 safety meta-analysis & 503A pharmacy data
Continuing Education
Go deeper than the summary
Dr. Schuster's board-certified, accredited peptide therapy course: 5 CEUs of peer-reviewed research, full dosing protocols, and video breakdowns.